Andrew Hall, B. Med. Sci., M.Sc.

Chief Executive Officer

Andrew brings more than 20 years of executive experience in biopharmaceuticals and life science. He has spent his career focused on corporate and portfolio strategy, as well as business development and commercial operations with industry leaders such as Celgene, Merck, Schering-Plough and Bristol-Meyers Squibb spearheading new product development, analytics and commercial strategy for immunology & inflammation, oncology, women's health, cardiovascular portfolios and more. In his most recent roles with Celgene, Andrew had led new product analytics and commercial strategy for the Inflammation & Immunology division and led new critical alliances across all therapeutic areas. Andrew Hall holds a Master of Science from RMIT University and a Bachelor of Medical Science with Honors from Melbourne University.

Jeremy Graff, PhD

Chief Scientific Officer

Dr. Graff brings over 20 years of experience in preclinical, clinical research and translational analysis for novel immune-activating therapeutics in oncology. Most recently, Dr. Graff served as Chief Development Officer and Senior Vice President, Research at HiberCell, a biotechnology company developing novel therapeutics for cancer relapse and metastasis. He led the scientific and clinical development teams for HiberCell. Prior to that he was employed at Biothera Pharmaceuticals serving as President since 2018 and Chief Scientific Officer since 2014. In these executive roles, Dr. Graff implemented strategic translational studies along with clinical programs in immuno-oncology. He also managed corporate strategy for investor engagement and oversaw the acquisition of Biothera’s lead asset Imprime PGG by HiberCell, Inc in 2020. Dr. Graff spent 16 years at Eli Lilly and Lilly Research Labs where he developed extensive experience in Cancer Drug Discovery and Development, immuno-oncology, biomarker discovery and patient stratification. During his last position at Eli Lilly as Group Leader, Cancer Biology and Patient Tailoring, he established a Translational Oncology Unit to improve the technical success of clinical trials. At Lilly Research Labs, he was the recipient of President’s Recognition Award, the Company’s highest annual award. Dr. Graff received a Ph.D. from the University of Kentucky’s Markey Cancer Center and completed a post-doctoral fellowship at the John Hopkins University Oncology Center. He has authored 60 peer-reviewed publications and holds a number of patents for novel cancer therapies.

Brittany Davison, CPA, CA

Chief Accounting Officer

With over 10 years of financial reporting experience, Brittany has provided key financial and operational leadership to IMV since she began working for the company in February 2014. She is responsible for financial reporting, tax and securities compliance, managing audit and internal control functions, budgeting and cash flow projections and IT oversight. Prior to joining the company, she began her career as an audit senior at Grant Thornton. Brittany graduated summa cum laude with a Bachelor of Commerce degree from Saint Mary’s University and is a Chartered Professional Accountant. Brittany volunteers with the Mental Health Foundation of Nova Scotia and is a member of the programming committee for Financial Executives International, Atlantic Chapter.

Linda Barabé, MBA

Senior Vice President, Human Resources and Internal Communications

Linda brings 25 years of global Human Resources experience with a career encompassing both international and domestic responsibilities. She has held leadership roles in various industries, from Engineering and Retail to Technology and Pharmaceuticals. Before joining IMV Inc., Linda was the Vice President of Human Resources for Baylin Technologies. Linda’s industry experience and expertise lie in change management, leadership development, diversity/inclusion, talent acquisition, mergers and acquisitions, and divestitures. Linda earned a Master’s in Business Administration from Royal Roads University in British Columbia, specializing in Strategic Human Resource Management.  She also serves on the HR committee for St Raphael, a non-profit palliative care home providing services for terminally ill patients.

Marie-Eve Charrois, MA

Vice President, Regulatory Affairs

Marie-Eve brings over 20 years of experience in the biopharmaceutical industry, mainly in vaccine development and commercial production. She has served in many roles of increasing responsibility in Regulatory Affairs and Quality. In her most recent position as Site Conformance Manager at GSK Vaccine, she was responsible for supporting the Quebec site in the regulatory strategies for post-approval changes, review, and approval of regulatory submissions, preparation to GMP inspections and their associated Quality Systems. She has spent 18 years at Medicago (a biotech company focused on vaccine development), the five last years as Director of Regulatory Affairs. She played a key role in the preparation of the regulatory dossier to support several Phase 1, 2, and 3 clinical trials conducted in Canada, USA, Europe, South Africa, and Australia. She has actively participated in formal and technical meetings with regulatory authorities (FDA, Health Canada BRDD, and EMEA) in the context of the vaccine development but also in the context of regulatory interactions associated with the maintenance of licensed vaccines. Marie-Eve owns a Master of Arts from Laval University in Quebec.

Stéphan Fiset, MSc, MBA

Vice President, Clinical Research

Stephan manages the implementation and progress of IMV’s clinical programs. Prior to joining the company, he worked for more than 15 years in clinical research with Medicago, GlaxoSmithKline and the Infectious Disease Research Center of the CHUL, where he led multifunctional teams in several therapeutic areas, including Oncology, HIV, Vaccines, Sepsis, Hematology, and Neurology. Throughout his career, he was involved in scientific and operational activities of several Phase I to Phase III trials. He has also led several process improvement teams to ensure timely and cost-effective delivery of clinical trials. Stephan received an MBA with honor from Université Laval and a Master degree in Microbiology from the University of Sherbrooke.

Heather Hirsch, PhD

Vice President, Translational Research

Heather brings more than 10 years of expertise in translational sciences having worked at Merck, Jounce Therapeutics and most recently CRISPR Therapeutics. She has a strong background in immune-oncology, tumor microenvironment, and integrative translational analyses designed to inform indication selection, mechanism of action, and responder identification. Heather also brings strong expertise in computational biology and ‘omics level analyses. Throughout her career, Heather has been involved in many preclinical and clinical stage small molecule, biologics (including Keytruda), and cell therapy based programs. She has led translational efforts across drug development stages from Target Identification through to phase III trials including driving companion diagnostic development. Heather holds a PhD in Cell and Molecular Biology from Michigan State University and completed post-doctoral fellowship at Harvard Medical School with much of her research focus on gene expression regulation in cancer.